Drug class
Asthma Therapy - Biologics/Monoclonal Antibodies
Asthma Therapy - Biologics/Monoclonal Antibodies refers to a specialized therapeutic drug grouping consisting of targeted monoclonal antibodies indicated as add-on maintenance treatment for moderate-to-severe, uncontrolled asthma. Read more about Asthma Therapy - Biologics/Monoclonal Antibodies
12 drugs in this class 7 manufacturers
Drugs in Asthma Therapy - Biologics/Monoclonal Antibodies
EXDENSUR (depemokimab-ulaa)
OMLYCLO (omalizumab-igec)
Asthma Therapy - Biologics/Monoclonal Antibodies refers to a specialized therapeutic drug grouping consisting of targeted monoclonal antibodies indicated as add-on maintenance treatment for moderate-to-severe, uncontrolled asthma.
Rather than providing broad immunosuppression, these agents function by selectively binding and neutralizing specific inflammatory mediators—such as immunoglobulin E (anti-IgE), interleukins 4, 5, and 13 (anti-IL-5, anti-IL-5 receptor, and anti-IL-4/IL-13), or thymic stromal lymphopoietin (anti-TSLP)—thereby halting key cascades driving chronic airway inflammation.
Their principal clinical role is to diminish exacerbations, enhance lung function, and reduce reliance on oral corticosteroids in severe eosinophilic or allergic asthma phenotypes.
Several agents within this class also extend therapeutically to overlapping type 2 inflammatory conditions, including chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and atopic dermatitis.
-
nih.gov
Asthma Therapy - Biologics/Monoclonal Antibodies refers to a specialized therapeutic drug grouping consisting of targeted monoclonal antibodies indicated as add-on maintenance treatment for moderate-to-severe, uncontrolled asthma Rather than providing broad immunosuppression, these agents function by selectively binding and neutralizing specific inflammatory mediators—such as immunoglobulin E (anti-IgE), interleukins 4, 5, and 13 (anti-IL-5, anti-IL-5 receptor, and anti-IL-4/IL-13), or thymic st...
-
thoracic.org
Asthma Therapy - Biologics/Monoclonal Antibodies refers to a specialized therapeutic drug grouping consisting of targeted monoclonal antibodies indicated as add-on maintenance treatment for moderate-to-severe, uncontrolled asthma Rather than providing broad immunosuppression, these agents function by selectively binding and neutralizing specific inflammatory mediators—such as immunoglobulin E (anti-IgE), interleukins 4, 5, and 13 (anti-IL-5, anti-IL-5 receptor, and anti-IL-4/IL-13), or thymic st...
-
nih.gov
Rather than providing broad immunosuppression, these agents function by selectively binding and neutralizing specific inflammatory mediators—such as immunoglobulin E (anti-IgE), interleukins 4, 5, and 13 (anti-IL-5, anti-IL-5 receptor, and anti-IL-4/IL-13), or thymic stromal lymphopoietin (anti-TSLP)—thereby halting key cascades driving chronic airway inflammation
-
fda.gov
Their principal clinical role is to diminish exacerbations, enhance lung function, and reduce reliance on oral corticosteroids in severe eosinophilic or allergic asthma phenotypes
-
nih.gov
Their principal clinical role is to diminish exacerbations, enhance lung function, and reduce reliance on oral corticosteroids in severe eosinophilic or allergic asthma phenotypes
-
fda.gov
Several agents within this class also extend therapeutically to overlapping type 2 inflammatory conditions, including chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and atopic dermatitis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.